Champions Oncology, Inc. last reported quarterly results on Sep 10, 2026, for Q1 FY2027 (the quarter ended Jul 31, 2026): revenue of $15.2 million (+8.8% year over year). It usually reports 40–46 days after a quarter ends. Based on that pattern, the next release is estimated for around Dec 14, 2026.
Results for Q2 FY2027, the quarter ending around Oct 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Dec 15, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 40–46 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Sep 10, 2026
41 days after quarter end
|
Q1 FY2027
ended Jul 31, 2026
|
15
+8.8%
|
-0
+8.6%
|
—
|
|
Mar 12, 2026
40 days after quarter end
|
Q3 FY2026
ended Jan 31, 2026
|
17
-2.8%
|
-0
-106.2%
|
-0.02
-106.5%
|
|
Dec 15, 2025
45 days after quarter end
|
Q2 FY2026
ended Oct 31, 2025
|
15
+11.5%
|
0
-63.2%
|
0.02
-60.0%
|
|
Sep 15, 2025
46 days after quarter end
|
Q1 FY2026
ended Jul 31, 2025
|
14
-0.5%
|
-0
-135.5%
|
-0.03
-133.3%
|
|
Mar 11, 2025
39 days after quarter end
|
Q3 FY2025
ended Jan 31, 2025
|
17
+41.8%
|
4
+277.7%
|
0.31
+263.2%
|
|
Dec 11, 2024
41 days after quarter end
|
Q2 FY2025
ended Oct 31, 2024
|
13
+16.6%
|
1
+135.2%
|
0.05
+133.3%
|
|
Sep 11, 2024
42 days after quarter end
|
—
ended Jul 31, 2024
|
—
|
—
|
—
|
|
Mar 12, 2024
41 days after quarter end
|
—
ended Jan 31, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CSBR (Nasdaq)
- Fiscal year ends
- April 30
- Incorporated in
- DE
- Headquarters
- Baltimore, MD
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 771856
- Former names
- CHAMPIONS BIOTECHNOLOGY, INC. (until Mar 30, 2011); CHAMPIONS SPORTS INC (until Feb 16, 2007)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.